Description
This research blend combines two complementary growth hormone–axis peptides in a single nasal spray formulation: CJC-1295 (no DAC), a modified GHRH(1-29) analog, and ipamorelin, a selective ghrelin/GHS-R agonist. The pairing allows concurrent investigation of GHRH receptor and growth hormone secretagogue receptor pathways from two structurally distinct mechanisms. CJC-1295 (no DAC), also known as Mod GRF 1-29, is a 29-amino-acid GHRH analog with four substitutions (D-Ala2, Gln8, Ala15, Leu27) designed to resist DPP-IV cleavage while maintaining a short pulsatile half-life. Ipamorelin is a synthetic pentapeptide studied for its selective ghrelin receptor activation with minimal off-target activity at cortisol, prolactin, ACTH, and aldosterone pathways.
Product Highlights
• Each vial contains 10 mL solution (~100 sprays)
• Each spray delivers 0.1 mL = 50 mcg CJC-1295 (no DAC) + 50 mcg Ipamorelin
• Total CJC-1295 (no DAC) Content: 5 mg per vial
• Total Ipamorelin Content: 5 mg per vial
• Total Peptide Content: 10 mg per vial
• Specialized pharmaceutical-grade nasal solution — designed for comfort and ease on the nose
• Unlike many other nasal sprays, this formula avoids irritation and dryness
• Packaged in Class A, lead-free pharmaceutical glass bottles
• Tamper/Child-Proof Cap + Orifice Reducer for integrity, sterility, and ease of use
This dual-peptide nasal spray is explored for combined activation of the GHRH receptor (via CJC-1295 no DAC) and the growth hormone secretagogue receptor / GHS-R1a (via ipamorelin), with research interest in pulsatile growth hormone release, IGF-1 dynamics, body composition endpoints, and receptor selectivity profiles in somatotropic axis investigations.
Benefits
• Dual-pathway activation — combined GHRH receptor + GHS-R agonism studied for synergistic GH release
• DPP-IV resistance — CJC-1295 (no DAC) modifications confer enzymatic stability and extended action vs native GRF
• Ipamorelin selectivity — explored for minimal cortisol, prolactin, and ACTH off-target effects
• Pulsatile preservation — investigated for maintaining physiological GH pulsatility unlike exogenous GH
• IGF-1 signaling — examined for downstream hepatic IGF-1 production and somatotropic endpoints
• Body composition research — investigated in aged rodent models and somatopause endpoints
Localized Effects with Nasal Spray
• Rapid absorption through the nasal mucosa
• Bypasses first-pass hepatic metabolism that limits oral peptide bioavailability
• Convenient delivery route for paired-peptide research protocols requiring repeated dosing
• Co-administration in a single vehicle enables synchronized pharmacokinetic studies
• Formulated with a specialized isotonic nasal vehicle to minimize irritation and dryness
What Researchers Use It For
• Combined GHRH receptor and GHS-R1a pharmacology studies
• Pulsatile GH release dynamics under dual-pathway stimulation
• IGF-1, IGFBP-3, and somatotropic axis endpoint research
• DPP-IV resistance and peptide pharmacokinetic profiling
• Cortisol, prolactin, and ACTH selectivity profiling
• Comparative pharmacology versus other GHRH/GHS-R combinations
Identity & Specs
• Compound 1: CJC-1295 without DAC (Mod GRF 1-29)
• Class: Modified GHRH(1-29) analog with D-Ala2, Gln8, Ala15, Leu27 substitutions
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
• Formula / M.W.: C152H252N44O42, ~3367.95 g/mol
• CAS: 863288-34-0
• Compound 2: Ipamorelin
• Class: Selective ghrelin / GHS-R1a agonist (pentapeptide)
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2
• Formula / M.W.: C38H49N9O5, ~711.85 g/mol
• CAS: 170851-70-4
• Form: Sterile nasal spray solution
• Net per vial: 10 mL (~100 sprays)
• Total Content: 10 mg combined peptide per vial
• Concentration: CJC-1295 (no DAC) 0.5 mg/mL + Ipamorelin 0.5 mg/mL
• Purity: ≥99% by HPLC (per component)
• Identity: MS-verified (per COA)
• Storage: Refrigerate 2–8 °C, protect from light
⚠️ Disclaimer
This product is intended for laboratory research use only.
Not for human or veterinary use.
Not approved for diagnostic, therapeutic, or medical applications.
Handle using appropriate laboratory safety procedures and personal protective equipment.
JANOSHIK COA – THIRD-PARTY TESTING
https://janoshik.com/tests/93318-CJC1295Ipamorelin_5mg5mg_VPeptide_Canada_PIQC9HTSNN6P – December 11 2025
121732-CJCIPA_VPeptide_Canada_1UYTSEGTB142 – March 16 2026